COVID-19 Clinical Trial Pipeline Advances With 180+ Companies and 200+ Therapies

The COVID-19 clinical trial pipeline continues to demonstrate substantial research activity, with more than 180 companies developing over 200 pipeline therapies across different stages of clinical and nonclinical development. DelveInsight’s “COVID-19 Pipeline Insight 2026” report provides a detailed assessment of emerging therapeutics, clinical strategies, drug mechanisms, development stages, routes of administration, and commercial opportunities within the COVID-19 treatment landscape.

(Albany, New York, USA) September 05, 2026- DelveInsight’s “COVID-19 Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the COVID-19 Pipeline @ COVID-19 Pipeline Outlook - https://www.delveinsight.com/report-store/covid-19-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Key Developments in the COVID-19 Clinical Trial Pipeline

• Recent clinical research demonstrates continued efforts to improve prevention and treatment strategies for different COVID-19 populations. On September 01, 2026, Wits Health Consortium (Pty) Ltd highlighted a study evaluating the effectiveness of a homologous boost of the Ad26.COV2.S COVID-19 vaccine following the prime dose among Sisonke participants in South Africa. The study aims to evaluate vaccine effectiveness among boosted, unboosted, vaccinated, and unvaccinated populations.
• On August 25, 2026, Pfizer conducted a Phase III study evaluating the efficacy and safety of ibuzatrelvir, both alone and in combination with intravenous remdesivir, compared with remdesivir alone. The study focuses on severely immunocompromised adults with symptomatic COVID-19 who are hospitalized or non-hospitalized at baseline with mild-to-moderate disease.
• DelveInsight’s COVID-19 Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for COVID-19 treatment.
• The leading COVID-19 Companies such as Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.
• Promising COVID-19 Pipeline Therapies such as Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.

Get insights into COVID-19 clinical trials, emerging therapies, and leading companies with DelveInsight @ COVID-19 Treatment Drugs - https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

COVID-19 Disease Overview and Ongoing Therapeutic Needs

COVID-19 is an infectious disease caused by SARS-CoV-2, a virus capable of evolving through genetic changes and mutations. Clinical manifestations can range from asymptomatic infection to severe respiratory disease. Common symptoms include fever, cough, fatigue, shortness of breath, sore throat, headache, and muscle aches. Loss of taste or smell has also been associated with COVID-19, while some patients may experience gastrointestinal symptoms.

Severe disease can progress to pneumonia, respiratory distress, and multi-organ complications. The continuing emergence of viral variants has supported the need for adaptable preventive and therapeutic approaches. Consequently, researchers continue to investigate antiviral agents, antibodies, vaccines, immune-based therapies, and other treatment strategies designed to address evolving clinical requirements.

Emerging COVID-19 Drugs and Pipeline Therapies

Several emerging candidates illustrate the diversity of approaches being explored across the COVID-19 pipeline.

VYD-2311, developed by Invivyd, Inc., is a monoclonal antibody candidate intended to provide prophylactic and therapeutic options for COVID-19. Its development incorporates molecular evolution designed to optimize neutralization against contemporary SARS-CoV-2 lineages. The candidate is currently being evaluated in Phase III development.

Ibuzatrelvir (PF-07817883), developed by Pfizer, is an investigational oral SARS-CoV-2 main protease inhibitor. It is designed to work without ritonavir boosting, potentially simplifying treatment and reducing certain drug-drug interaction concerns. The therapy is currently being evaluated in Phase III development.

N-803, developed by ImmunityBio, Inc., is an interleukin-15 superagonist fusion protein designed to stimulate natural killer and CD8+ T-cell responses. It is currently being investigated in Phase II development for COVID-19.

ENTVAX002, also known as Covigenix VAX-002, is an investigational plasmid DNA vaccine developed by Entos Pharmaceuticals Inc. in partnership with Aegis Life. The vaccine is designed to address emerging SARS-CoV-2 variants and is currently in Phase II development.

ALG-097558, developed by Aligos Therapeutics, is a ritonavir-free pan-coronavirus protease inhibitor. Preclinical research has demonstrated activity against multiple SARS-CoV-2 variants, as well as broader coronavirus targets. The candidate is currently being evaluated in Phase II development.

RBM001, MDX2301, and PA-001 represent additional early-stage approaches. RBM001 is a protein-based vaccine designed to target conserved regions of the viral spike protein, while MDX2301 is a multispecific antibody intended to neutralize diverse SARS-CoV-2 variants. PA-001 is a peptide-based inhibitor targeting the S2 domain of the spike protein and is being evaluated in Phase I development.

Explore groundbreaking therapies and clinical trials in the COVID-19 Pipeline @ New COVID-19 Drugs - https://www.delveinsight.com/sample-request/covid-19-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

COVID-19 Pipeline Assessment and Development Landscape

The COVID-19 Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The COVID-19 Pipeline Report also highlights the unmet needs with respect to the COVID-19.

The report evaluates companies developing COVID-19 therapies and provides an assessment of their respective pipeline assets. It examines therapeutic candidates across early-, mid-, and late-stage development and identifies active, dormant, and discontinued projects.

The analysis also categorizes COVID-19 drugs according to clinical development stage, route of administration, target receptor, mechanism of action, molecular type, and use as monotherapy or combination therapy. In addition, the report examines company-company and company-academia collaborations, licensing agreements, and financing activities supporting future development.

Learn about new COVID-19 drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ COVID-19 Market Drivers and Barriers - https://www.delveinsight.com/report-store/covid-19-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Scope of the COVID-19 Pipeline Report

The report provides global coverage of the COVID-19 pipeline landscape and evaluates major companies and therapies under development. Key therapies include Calcium Dobesilate, Mannitol, Interferon-Alpha2B, WPV01, ILT101, Ibuzatrelvir, Remdesivir, and others.

Coverage- Global

COVID-19 Companies- Ansun Pharm, Biophytis, MetrioPharm, GeneOne Life Science, Shionogi, Sinocelltech, Laurent Pharmaceuticals, Frontier Biotechnologies, Eyegene, aptaTargets, Veru Inc., Corvus Pharmaceuticals, Revive Therapeutics, Regeneron Pharmaceuticals, Hoffmann-La Roche, CytoDyn, Incyte Corporation/Novartis, SAB Biotherapeutics, Moderna Therapeutics, Pfizer, FibroGen, Arch Biopartners, Senhwa Biosciences, Ionis Pharmaceuticals, GlycoMimetics, Akari Therapeutics, Serpin Pharma and others.

Conclusion

The COVID-19 clinical trial pipeline continues to evolve, supported by extensive research across antiviral therapies, monoclonal antibodies, vaccines, peptides, immune-based approaches, and other innovative modalities. With more than 180 companies and 200 pipeline therapies, the development landscape encompasses candidates from discovery through Phase III. Emerging therapies such as VYD-2311, ibuzatrelvir, ENTVAX002, ALG-097558, RBM001, MDX2301, and PA-001 demonstrate the diversity of approaches being explored. Continued clinical research, technological innovation, and evaluation of emerging SARS-CoV-2 variants are expected to remain important areas of focus for COVID-19 therapeutic development globally.